 SARASOTA, Fla., Aug. 5, 2021 PRNewswire -- INVO Bioscience, Inc. NASDAQ: INVO, a medical device company focused on commercializing the worlds only in vivo Culture System IVC, INVOcell, an effective and affordable treatment for patients diagnosed with infertility, will report financial results for its second quarter 2021, ended June 30, 2021, after the market close on Monday, August 16, 2021. 